Literature DB >> 32366714

Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment".

Andreas H Diacon1,2, Veronique R De Jager2, Rodney Dawson3, Kim Narunsky3, Naadira Vanker4, Divan A Burger5, Daniel Everitt6, Frances Pappas6, Jerry Nedelman6, Carl M Mendel6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32366714      PMCID： PMC7318045          DOI： 10.1128/AAC.00709-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  3 in total

1.  Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.

Authors:  Francesca Conradie; Andreas H Diacon; Nosipho Ngubane; Pauline Howell; Daniel Everitt; Angela M Crook; Carl M Mendel; Erica Egizi; Joanna Moreira; Juliano Timm; Timothy D McHugh; Genevieve H Wills; Anna Bateson; Robert Hunt; Christo Van Niekerk; Mengchun Li; Morounfolu Olugbosi; Melvin Spigelman
Journal:  N Engl J Med       Date:  2020-03-05       Impact factor: 91.245

2.  Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment.

Authors:  Hannah Yejin Kim; Shashikant Srivastava; Hemanth Kumar Ak; Ben J Marais; Jan-Willem Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.

Authors:  Andreas H Diacon; Veronique R De Jager; Rodney Dawson; Kim Narunsky; Naadira Vanker; Divan A Burger; Daniel Everitt; Frances Pappas; Jerry Nedelman; Carl M Mendel
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.